glp 1 agonist fda approved for weight loss approves Foundayo, an oral GLP-1 alternative to Wegovy and Ozempic New GLP-1 Pill Foundayo (Orforglipron)

Pfizers dose-optimization studies of once-daily formulations of danuglipron ( NCT06567327 and NCT06568731 ) met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver a competitive efficacy and tolerability profile in Phase 3 testing, based on earlier studies of twice-daily danuglipron

Providers on our platform can now send prescriptions for Zepbound vials and KwikPen, as well as Foundayo, to the LillyDirect pharmacy and access self-pay pricing for Hims & Hers customers.

Discover clinical trial results and which GLP-1 medication may be right for you.

Adolescents with obesity prescribed a GLP-1 receptor agonist are less likely to have suicidal ideation or a suicide attempt than those with obesity treated with lifestyle intervention, according to new data

Eli Lilly has just launched its newly approved GLP-1 product, Zepbound, in a direct-to-consumer approach